Ablynx Archives

Expert Advice 20 Mar 2023

Nine tips to succeed in pharma-biotech partnerships

The question of whether to partner with another company is critical to the long-term development of a biotech. Nonetheless, it can be easy for a small company to underestimate the resources it needs to put into a successful collaboration. Here, we’ll go over some expert advice on what to do and what not to do […]

March 20, 2023 - 9 minutesmins - By Alexander Burik

agrosavfe belgium strawberry pesticide fungal

News and Trends 30 Jul 2019

Belgian Biotech Raises €35M to Develop Eco-Friendly Pesticides

The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired by llama antibodies. AgroSavfe will use the funds to develop and manufacture its lead protein fungicide on a commercial scale. The company aims to get approval from the US Environmental Protection Agency and launch the […]

July 30, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Sep 2018

The EMA Approves the First Nanobody from Ablynx

Update: The EMA has officially approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura, following its earlier recommendation in June. The drug has also been accepted for priority review by the US FDA, with a decision due on 6 Feb 2019. Published 29.6.18 Just a few months after Sanofi acquired Ablynx in a multi-billion euro […]

September 4, 2018 - 2 minutesmins - By Editorial Team

Interview 30 May 2018

How to Close a €3.9B Acquisition Deal for Your Biotech Company

Ablynx, one of the big giants in the European biotech arena, closed the final stages of its €3.9B acquisition deal with Sanofi earlier this month, after details were announced in January. Edwin Moses, CEO of Ablynx, shared the company’s success story with attendees at our recent Refresh Meetup in Brussels. The technology behind Ablynx’s success […]

May 30, 2018 - 7 minutesmins - By Helen Albert

News and Trends 29 Jan 2018

Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B

Sanofi will acquire Ablynx and get its hands on the biotech’s exciting Nanobody technology just months after the biotech joined Europe’s billion-euro biotech club. Despite rejecting the advances of Novo Nordisk earlier this month, a decision that led to a 60% jump in Ablynx’s stock, the biotech has voted unanimously in favor of being acquired Sanofi. Sanofi has […]

January 29, 2018 - 3 minutesmins - By Alex Dale

More News! 9 Jan 2018

Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […]

January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 9 Jan 2018

Happy 2018, Here Are the Top 9 European Biotech Companies To Watch

As the 2017 reports roll in, we’re already turning our gaze to 2018. These are the top European biotech companies to watch in the new year. The results from last year are rolling in, and it seems to be a mixed bag. Generalist investors are backing away from biotech, but the FDA approved a record […]

January 9, 2018 - 5 minutesmins - By Evelyn Warner

Best in Biotech 18 Dec 2017

Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017

Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […]

December 18, 2017 - 9 minutesmins - By Alex Dale

Interview 11 Dec 2017

Edwin Moses on how Ablynx has made it to the top of European biotech

Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the biggest European biotechs. Ablynx, based in Belgium, has just recently joined the European billion-euro biotech club with a market cap of €1.45Bn. With positive Phase III results for its lead compound and a $230M (€195M) […]

December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 5 Dec 2017

Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017

Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with its year-end lists of the top things that happened this year. First up, the best biotech companies of 2017! After the doozy of 2016 for biotech and pharma, things could only get better this year — and the European industry […]

December 5, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 4 Oct 2017

Ablynx Launches $175M IPO on Wall Street After Phase III Success

Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […]

October 4, 2017 - 2 minutesmins - By Alex Dale

sobi hemophilia clotting factor alprolix

News and Trends 2 Oct 2017

Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder

Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood disorder with caplacizumab. Ablynx develops nanobodies, molecules with the specificity of antibodies but much smaller in size. Its product, caplacizumab, has received encouraging results for the treatment of the life-threatening autoimmune blood disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which […]

October 2, 2017 - 3 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us